Research brief · 2026-09-09
What Does Semax Actually Do? What the Research Shows
Semax is a synthetic seven-amino-acid peptide. It is built from a fragment of adrenocorticotropic hormone, ACTH 4-10, with a three-amino-acid Pro-Gly-Pro tail added on. It was developed in Russia, where the medical literature describes it as a domestically registered drug given as nasal drops or spray, studied mainly as a neuroprotective and cognitive agent. It is not approved as a medicine in the United States, the EU or the UK.
There is a real body of published human research on Semax, but it has a consistent shape: every study located is Russian, small, and not blinded. Almost all appeared in one journal, Zhurnal Nevrologii i Psikhiatrii. None is described as double-blind or placebo-controlled.
The largest is a 2018 study by Gusev and colleagues in about 110 patients recovering from ischemic stroke. It compared Semax-treated patients against those receiving conventional therapy, not against a placebo. A 1997 study by the same group compared 30 treated stroke patients with 80 conventional-therapy controls. An optic nerve study by Polunin and colleagues in 2000 compared two ways of giving the same drug rather than testing it against nothing.
The most telling result comes from a 2007 open-label study by Serdiuk and colleagues in motor neuron disease. Semax did not change the underlying nerve-damage measurements the researchers tracked with needle EMG, although patients scored better on a quality-of-life questionnaire, which is exactly what an unblinded design tends to produce.
The limit is fundamental. Zero Semax trials are registered on ClinicalTrials.gov, no dose-ranging study exists, no study followed people for more than a few months, and no blinded placebo comparison has ever been run. That means no one can yet separate a real drug effect from expectation or the natural course of the condition. Semax is not approved for human use outside Russia.
Sources
- Gusev EI et al., The efficacy of semax in patients at different stages of ischemic stroke, n=110, not blinded or placebo-controlled
- Zhurnal Nevrologii i Psikhiatrii 2018
- Serdiuk AV et al., chronic partial denervation and quality of life in motor neuron disease treated with semax, open-label
- Zhurnal Nevrologii i Psikhiatrii 2007
- Gusev EI et al., Effectiveness of semax in acute hemispheric ischemic stroke, n=30 vs 80 controls, not blinded
- Zhurnal Nevrologii i Psikhiatrii 1997
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.